



# Bioinorganic Chemistry and Applications

Special Issue on

## Inorganic Pharmaceuticals on Cancer Imaging and Precise Cancer Therapy

# CALL FOR PAPERS

There has been a long-standing interest in developing inorganic chemotherapeutic agents that can effectively prolong the surviving profile of cancer patients. In the past two decades, a number of advances in inorganic therapeutics have been approved by the Food and Drug Administration (FDA), and many more are under active clinical investigation. Overall, the principle of drug development is often derived from a new understanding of inorganic chemistry, followed by a smart application designed to solve an emerging clinical challenge. For instance, the design and the successful clinical application of PSMA-617, a  $^{177}\text{Lu}$  labeled DOTA derivatives of PSMA, have become a landmark for prostate cancer treatment and the related PET image was awarded as “Image of the Year 2015” on Nuclear Medicine Annual Meeting. In addition to the clinical successes, the scientific rationale of developing inorganic cancer-targeting therapeutics is also greatly inspiring, not only for the research teams who are dedicated on cancer treatment, but also to the most general audiences including chemists, biologists, and clinical doctors who have interest in utilizing chemistry to guide clinical advances. For a better understanding of the current progresses in this field, we would like to launch a special issue that addresses the importance of the biological design, chemical screening, and clinical application of anticancer inorganic pharmaceuticals, with focusing on imaging-guided early stage cancer diagnosis and precision therapy.

This special issue will be highly interested to scientists and clinicians who are working on bench-to-bedside translation, including inorganic chemists, oncology clinicians, molecular biologists, imaging scientists, pharmaceutical developers, and physicists. Both academic and clinical researchers are invited to submit the manuscript.

Potential topics include, but are not limited to:

- ▶ New metal-chelating chemistry for developing cancer-targeting radiopharmaceuticals
- ▶ New bioconjugate chemistry for developing inorganic cancer therapeutics
- ▶ New inorganic nanotechnology for cancer theranostics
- ▶ Translational medicine research on new inorganic cancer-targeting imaging probes and therapeutics
- ▶ New clinical application of traditional inorganic anticancer drugs

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bca/ipip/>.

### Lead Guest Editor

Zhibo Liu, National Institutes of Health, Bethesda, USA  
[zhibo.liu@nih.gov](mailto:zhibo.liu@nih.gov)

### Guest Editors

Zhi Yang, Peking University, Beijing, China  
[pekyz@163.com](mailto:pekyz@163.com)

Hao Hong, University of Michigan, Ann Harbor, USA  
[hahong@med.umich.edu](mailto:hahong@med.umich.edu)

X. Shen, Peking University, Beijing, China  
[xshen@pku.edu.cn](mailto:xshen@pku.edu.cn)

### Manuscript Due

Friday, 19 August 2016

### First Round of Reviews

Friday, 11 November 2016

### Publication Date

Friday, 6 January 2017